Applying at least one-adrenergic agonist as an antagonist of substance p

 

(57) Abstract:

The invention relates to medicine, namely to dermatology, and concerns the use of at least one adrenergic agonist in cosmetic compositions as an antagonist of substance P for the treatment of diseases associated with excessive synthesis and/or release of substance P. the Invention can significantly reduce or eliminate irritating compounds that are commonly used in cosmetics or pharmaceuticals. 5 C. and 10 C.p. f-crystals, 2 tab.

The present invention relates to the use of at least one adrenergic agonist in cosmetic compositions as an antagonist of substance P or to obtain pharmaceutical compositions, more particularly dermatological compositions intended for the treatment of diseases associated with excessive synthesis and/or release of substance P.

The invention also relates to cosmetic or pharmaceutical compositions for topical application containing at least one adrenergic agonist.

Finally, the invention relates to a method of cosmetic treatment to reduce the pain associated with excessive sinthasomphone, containing-adrenergic agonist, applied to the skin, hair and/or mucous membranes.

The mammals include polypeptides belonging to the family of tachykinins, which induce a rapid decrease in the ratio of smooth muscle fibers. From among the compounds of this family include neurokinin , neurokinin and substance P.

Substance P is a polypeptide (undecapeptide) chemical component, which is produced and secreted by the nervous finish. Localization of substance P-specific neurons in the Central nervous system and organs in the periphery. Thus, a large number of organs or tissues take neural afferents containing substance P, in particular the salivary glands, stomach, pancreas, intestine (in the latter case, the distribution of substance P is superimposed on the inner nervous plexus of Meissner and Auerbach), cardiovascular system, thyroid gland, skin, iris and ciliary body, the bladder and, obviously, the peripheral and Central nervous system.

Due to the widespread distribution of substance P, many diseases are associated with excessive synthesis and/or in rvnoy system (for example, anxiety, psychosis, neuropathy, neurodegenerative disorders such as senile dementia in Alzheimer's disease, dementia associated with AIDS, Parkinson's disease, down's syndrome, Korsakov's syndrome, multiple sclerosis or schizophrenia), diseases of the respiratory organs (e.g., pneumonia), and inflammatory diseases such as rheumatoid arthritis), allergic syndromes (such as asthma, allergic rhinitis, allergic pharyngitis, urticaria or exanthematous dermatitis), gastrointestinal diseases (such as ulcers, colitis or Crohn's disease), in skin diseases (such as psoriasis, disorders causing itching, herpes, photodermatosis, diffuse neurodermatitis, contact dermatitis, psoriasis, prurigo, Judy, erythema, particularly sunburn or insect bites), fibrosis and other disorders of maturation of collagens (such as scleroderma), in cardiovascular disease, vasospastic disorders (such as migraine or Raynaud's disease), immunological disorders, disorders of the urinary tract (such as incontinence or cystitis), rheumatic diseases, when defined, waity, eye Sudy, eye pain or irritation).

The use of an antagonist of the substance P is one of the most effective therapeutic alternatives for all the above mentioned conditions.

It is understood that the antagonist of the substance P is any compound which is capable of partially or completely suppress the biological effect of substance P. In particular, for the recognition of matter as an antagonist of substance P it must make a coherent pharmacological response (including or not including its binding to the receptor for substance P), in particular, in one of the following tests:

- the substance is an antagonist should reduce the allocation of plasma through the vascular wall induced by capsaicin or antidrain nerve stimulation, or, in the alternative case,

- the substance is an antagonist should cause inhibition of the reduction of smooth muscles induced by the introduction of substance P.

Currently antagonists substance P is used to treat the above diseases.

Found that-adrenergic agonists meet the criteria for antagonists of substance P.

Thus, the invention relates to the use of at least one adrenalectomies to the use of at least one adrenergic agonist in obtaining pharmaceutical compositions intended for the treatment of diseases associated with excessive synthesis and/or release of substance P. In pharmaceutical compositions-adrenergic. agonist is preferably used as an antagonist of substance P.

Compositions according to the invention is preferably intended for topical application.

In addition, the present invention relates to a method of cosmetic treatment, which consists in the fact that it uses the cosmetic composition defined in accordance with the invention.

-Adrenergic agonists are sympathomimetic molecules that reproduce the effects of stimulation of the sympathetic nerves.

Sympathomimetic utilities affect the fibers of smooth muscle tissue. Their prototype is the adrenaline. There are receptors of different nature or sympathomimetic tools that are more active with respect to specific receptors than others. So is the case-adrenergic agonist that is specific to a-adrenergic receptors (which themselves are divided into two main subtypes, namely B1and B2).

Description is soriana (US 4,038,417), or, alternatively, as a tool that can be used in bathrooms to give the skin the sensation of freshness and to make the body feel the heat (JP-A-07258067). However, the prior art not known to the involvement of substance P in case of complaints, against which you want to use the described compositions, and to a still lesser degree this applies to any relationship between substance P and-adrenergic agonists. Never described the use of-adrenergic agonists as antagonists of substance P.

From the number of-adrenergic agonists that can be used in accordance with the invention, mention can be made of the salbutamol, isoproterenol, CGP12177, nylidrin, salmeterol, fenoterol, terbutaline or pirbuterol.

In accordance with the invention, it is preferable to use a salbutamol.

The number of-adrenergic agonist that can be used in accordance with the invention, of course, depends on the desired effect and from nature used agonist. To illustrate, in accordance with the invention, the agonist can be used in the range from 10-8up to 10 wt.% from the total mass of the composition and preferably in amounts of from 10 to 4 wt.% from somnium substance P, described earlier in the text.

Thus, a more specific object of the invention is the use of at least one adrenergic agonist in cosmetic compositions or pharmaceutical compositions intended for the treatment of skin diseases such as psoriasis, disorders causing itching, urticaria, atopic dermatitis, contact dermatitis, fibrosis, impaired maturation of collagen and usually causing itching and/or weighted dermatitis.

Moreover, in the field of skin diseases it is known that certain skin types are more sensitive than others. Phenomena such as skin irritations and/or sores and/or erythema and/or aesthetic feelings, and/or burning sensation, and/or itching of the skin and/or mucous membranes often associated with this increased sensitivity.

But still the symptoms of sensitive skin were poorly described, and for this reason, this problem has been poorly defined. However, it is not known what processes are involved in skin sensitivity. Assumed, sensitive skin is skin that reacts to cosmetic products, others believed that this was due to skin the cat is to the skin also classified as allergic skin.

Developed tests to determine sensitive skin, such as tests with lactic acid and DMSO, which are known to be irritant substances: see, for example, the article by K. Lammintausta and others, Dermatoses, 1988, 36, pages 45-49, and the article by T. Agner and J. Serup in Clinical and Experimental Dermatology, 1989, 14, pages 214-217.

Because of the neglect of the characteristics of sensitive skin still was very difficult, actually impossible, to cure them. Actually they were treated indirectly, for example by limiting the use in cosmetic or dermatological compositions irritating products of nature, such as surfactants, preservatives or fragrances, as well as the use of certain cosmetic or dermatological active ingredients.

After numerous clinical trials have an opportunity to identify the symptoms associated with sensitive skin. These symptoms are specific subjective symptoms, which are essentially aesthetic feeling. It is understood that under unaesthetic feelings mean more or less painful sensations in the skin area, such as burning, tingling, itching or pruritus, sensation of burning, sensations of heat, discomfort, Wasaga. Actually allergic skin is a skin that gives the reaction to foreign substance, allergen, which triggers an allergic reaction. This refers to the immunological process that occurs only when the allergen is present and which affects only entities with a given sensitivity. On the contrary, the essential characteristic of sensitive skin, from the point of view of the applicant, is the mechanism of response to external factors that may affect any individual, even if individuals with sensitive skin react to them more quickly than other individuals. This mechanism is not immunological: it is not specific.

The applicant has found that sensitive skin can be divided into two main clinical forms: irritable and/or reactive skin and intolerant skin.

Irritable and/or reactive skin is a skin which reacts by itching, i.e. by itching or burning, on various factors such as the environment, emotions, foods, the wind, rubbing, shaving, soap, surfactants, hard water with a high calcium concentration, temperature variations or wool. Typically, these signs are associated with the hat is the skin, which it reacts with sensations of heat, sudden sharp pain, tingling and/or redness at various factors such as the environment, emotions, foods, and certain cosmetic products. Typically, these signs are associated with hyperseborrhoea or prestoy skin, ulcers or without them and erythema.

"Sensitive" scalps have a less ambiguous clinical symptomatology: the sensation of itching and/or burning and/or heating are essentially triggered by local factors such as friction, soap, surfactants, hard water with a high calcium concentration, shampoos or lotions. These feelings sometimes also caused by factors such as the environment, emotions and/or food. With the above symptoms often associated erythema and hyperseborrhea scalp, as well as the presence of dandruff.

Moreover, in certain anatomic areas, such as the major folds (inguinal, genital, axillary, popliteal, anal, brisket or bends the elbow areas) and feet, sensitive skin is reflected in zadnych feelings and/or unaesthetic sensations (heat and/or burning), in particular related to sweat, friction, wool, surfactants, certain cosmetic prego to determine whether your skin is sensitive or not the applicant has also developed the test. In fact, after conducting a large number of tests to determine sensitive skin it was found that there was a relationship between people with sensitive skin and people who have a reaction to topical application of capsaicin.

The challenge with capsaicin is applied on approximately 4 square cm of skin 0.05 ml of a cream containing 0.075% capsaicin, and to observe the appearance of subjective signs caused by this application, such as sensations of burning pain, burn and itch. In subjects with sensitive skin such signs appear through 3-20 minutes after application and is followed by the appearance of erythema, which begins at the periphery of the zone of application.

At present, capsaicin is used as medicaments, in particular for the treatment of pain from herpes zoster. Capsaicin causes release of neuropeptides and, in particular, of tachykinins, which arise from the nerve endings in the epidermis and in fact in the skin. The applicant has found that fisiopatologia scheme common to all States sensitive skin, were related to high ability to select thik the "neurogenic".

No one has established a link between substance P and sensitive skin. Clinical signs of sensitive skin are essentially subjective: sharp pain, tingling, itching, backache or sensation of heat, and are typically associated with the eritem. These symptoms are due to non-specific external factors. The symptoms are essentially localized on the face, neck and scalp, and can also appear anywhere on the body.

Thus, the applicant has found that one of the essential characteristics of sensitive skin is associated with the release of substance P, and hence that the use of antagonists of substance P may be given the opportunity to obtain a protective and/or therapeutic effect on sensitive skin.

Thus, applicant provides for the use of antagonists of substance P for the treatment of sensitive skins. Actually, it was surprisingly found that the introduction of an antagonist of substance P in the song, intended for local use, prevents irritation, and/or aesthetic sensations and/or pruritus of the skin.

Therefore, the invention more specifically relates to the use of at least one adrenergic agonist in COSM treatment of sensitive skins.

Another object of the present invention, more specifically, is the use of at least one adrenergic agonist in cosmetic compositions or pharmaceutical compositions, and these compositions are designed to only to prevent and/or fight skin irritations and/or sores and/or eritem, and/or sensation of heat and/or aesthetic sensations and/or itching of the skin and/or mucous membranes.

-Adrenergic agonist can be used in the composition, which should be taken orally, or injected into injection, or, preferably, applied to the skin (any skin area of the body), the hair, the nails or the mucous membranes (buccal, zygomatic, gingival, genital, anal, or conjunctively). Depending on the method of introduction of the composition can be supplied in all commonly used pharmaceutical dosage forms.

Composition for injection can be supplied in the form of an aqueous lotion or oil suspensions, or in the form of a serum. To the eye it may be supplied in the form of drops, for internal administration it can be supplied in the form of capsules, granules, syrups or tablets.

Predpochtitel is the subject of the invention is a cosmetic or pharmaceutical composition for topical application, containing at least one adrenergic agonist.

The composition for topical application to the skin, in particular, may be in the form of aqueous or oil suspensions, or dispersions of the type of lotion or serum, in the form of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (M/B) or Vice versa (W/M), or in the form of suspensions or emulsions of soft consistency of the type of cream or aqueous or non-aqueous gel, or, in the alternative case, in the form of microcapsules or microparticles, or vesicular dispersions of ionic and/or nonionic type. These compositions have, in accordance with conventional methods.

They can also be used for the hair in the form of aqueous, alcoholic or aqueous-alcoholic solutions, or in the form of creams, gels, emulsions or foams, or, in the alternative case, in the form of aerosol compositions also containing a compressed propellant.

The amounts of the various components of the compositions according to the invention are the same as those usually used in this field.

In particular, these compositions form a cleansing, protective creams, creams for the treatment or care of the skin of the face, hands, feet, big anato is or creams against sunburn), liquid Foundation, cleansing milk to remove make-up, lotion protection or skin care, cleansing against tanning, lotions, gels or foams for caring for the body, such as cleansing lotions, lotions against tanning or lotions, tanning, compositions for the bath, deodorant compositions containing a bactericidal agent, gels or lotions after shaving, creams for hair removal, compositions against insect bites, composition against pain or compositions for treating certain skin diseases such as eczema, rosacea, psoriasis, lichens or severe itching.

The composition may also contain solid preparations consisting of cleansing Soaps or Soaps.

In addition, the composition can be packaged in the form of an aerosol composition, which also contains a compressed propellant.

-Adrenergic agonist used in accordance with the invention, may also be introduced into various compositions for hair care, including shampoos, lotions, hair styling, treatment lotions, creams and gels, hair styling, coloring compositions (in particular oxidation dyes), optionally in the form of shampoos to enhance color in lotions to restore hair structure, Kona or gels anti hair loss, in shampoos to combat parasites, etc.

It is also possible compositions for oral administration, for example toothpaste. In this case, the composition may contain auxiliary substances and additives conventional for songs cheek application, in particular surfactants, thickeners, humectants, polishing agents such as silica, various active ingredients such as fluorides, in particular sodium fluoride, and optionally sweeteners such as sodium saccharinate.

When the composition is an emulsion, the proportion of the fatty phase may range from 5 to 80 wt.% and preferably from 5 to 50 wt.% with respect to the total weight of the composition. Oils, waxes, emulsifiers and simulatory used in the composition in the form of an emulsion are chosen from those generally used in cosmetics. Emulsifier and simulator present in the composition in an amount of from 0.3 to 30 wt.% and preferably from 0.5 to 20 wt.% with respect to the total weight of the composition. In addition, the emulsion may contain lipid vesicles.

When the composition is an oily gel or solution, the fatty phase may represent more than 90% by weight of the total compositions which, the conventional in cosmetics, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, fragrances, fillers, protective agents, odor absorbers and coloring materials. The number of these various tools are the same as those usually used in cosmetics, for example, from 0.01% to 10% of the total weight of the composition. These auxiliary substances, depending on their nature, can be entered in the fatty phase, the induction phase and/or in the lipid field.

Among oils or waxes that can be used in the invention, mention can be made of mineral oils (liquid petrolatum), vegetable oils (liquid fraction of oil seed plants Butyrospermum Parkii, sunflower oil), animal oils (perhydrosqualene), synthetic oils (porcelanowe oil), silicone oils or waxes (cyclomethicone) and fluorinated oils (perforated polyethers), beeswax, Carnauba wax or paraffin wax. These oils can be added to the fatty alcohols and fatty acids (stearic acid).

Among the emulsifiers that can be used in the invention, mention can be made of, for example, literallayout,="ptx2">

Among the solvents that can be used in the invention, mention can be made of lower alcohols, in particular ethanol, isopropanol and propylene glycol.

From among hydrophilic gelling agents that can be used in the invention, mention can be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate/alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays, and from among the lipophilic gelling agents, mention can be made of modified clays, such as Bentone, salts of fatty acids with metals such as aluminum stearates, and hydrophobic silica, ethylcellulose or polyethylene.

The composition may contain other hydrophilic active ingredients, such as proteins or protein hydrolysates, amino acids, underground, urea, allantoin, sugars and derivatives of sugars, water-soluble vitamins, plant extracts and hydroxy acid.

As lipophilic active ingredients can be used retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides, essential oils or salicylic acid and its derivatives.

Cf is ugogo active means, intended in particular to prevent and/or treat skin conditions. Among these active agents may be mentioned, for example,

the money that modulate skin pigmentation and/or proliferation and/or differentiation, such as retinova acid and its isomers, retinol and its esters, vitamin D and its derivatives, astrogeny, such as estradiol, kojic acid or hydroquinone;

- antibacterial agents, such as clindamycine, erythromycin or antibiotics of the class tetracycline;

- a means of combating parasites, in particular metronidazole, crotamiton or pyrethroids;

- antifungal agents, in particular compounds belonging to the imidazole class, such as econazole, ketoconazole or miconazole or their salts, polyene compounds such as amphotericin B, compounds of the family of allylamines, such as terbinafine, or alternatively, octopirox;

- antiviral agents such as acyclovir;

- steroid anti-inflammatory agents such as hydrocortisone, betamethasone or globalatlanta, or non-steroidal anti-inflammatory drugs such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic is lidocaine and its derivatives;

- anti-itch, such as analgin, trimeprazine or cyproheptadine at;

- keratolytic agents such as hydroxycarboxylic acids or ketocarboxylic acids, their salts, amides or esters and more particularly, a hydroxy acid such as glycolic acid, lactic acid, salicylic acid, citric acid and fruit acids in General, and 5- (n-octanoyl) salicylic acid;

- anti-free radicals, such as-tocopherol or its esters, superoxide dismutase, chelating agents for some metals or ascorbic acid and its esters;

- antiseborrheic tools such as progesterone;

- protivopekhotnymi tools such as octopirox or zinc pyrithione;

- anti-acne, such as retinova acid or benzoyl peroxide.

Thus, in accordance with a particular variant of the invention relates to compositions containing at least one adrenergic agonist and at least one agent selected from antibacterial agents, tools for combating vermin, fungicides, anti-virus tools, anti-inflammatory drugs, anti-itching, means for anaesthesia, cdst, anti-acne and/or tools that modulate skin pigmentation and/or proliferation and/or differentiation.

Preferably, according to the present invention at least one adrenergic agonist may be combined with products with irritating, which is usually used in cosmetic or pharmaceutical products, which are sometimes cosmetic or pharmaceutical active ingredients. The presence of the antagonist of substance P in the form of at least one adrenergic agonist in cosmetic or pharmaceutical compositions containing the product with the irritant, can significantly reduce or actually eliminate this irritant effect. It additionally allows you to increase the number of the active component with irritating in relation to the number of commonly used component to improve efficiency.

Thus, the invention also relates to a cosmetic or pharmaceutical composition, preferably for topical use, containing in a cosmetically or pharmaceutically acceptable medium at least one product with the irritant, namely, with the irritant can be mentioned, for example, surfactants (ionic or nonionic), preservatives, organic solvents or active components, such as a-hydroxy acid (citric, malic, glycolic, tartaric, almond or lactic acid), a-hydroxy acid (salicylic acid and its derivatives), a keto acid, a keto acid, retinoids (retinol, retinal or retinova acid), anthralin (dioxiranes), anthranoid, peroxides (in particular benzoyl peroxide), Minoxidil, lithium salts, antimetabolites, vitamin D and its derivatives, dyes or hair dye (paraphenylenediamine and its derivatives or aminophenol), flavouring alcoholic solutions (perfume, toilet water, aftershave or deodorant), funds from sweat (certain aluminum salts), active ingredients for hair removal or permanent waving (thiols) or depigmenting active components (hydroquinone).

The use of an antagonist of substance P allows, in particular, to increase 2-10 times the amount of the active component with irritating compared to that typically used in order not tested any of the above-mentioned discomfort. It is possible to use hydroxy acid to 50% by weight of Coniah-adrenergic agonist can preferably be used in amounts in the range from 10-8up to 10 wt.% in relation to the total weight of the composition and, in particular, in amounts in the range from 10-5up to 4 wt.% in relation to the total weight of the composition.

It is obvious that the composition of the invention containing in a cosmetically or pharmaceutically acceptable medium at least one product with irritating and at least one adrenergic agonist, may be obtained in any known pharmaceutical dosage form, such as those described in the text.

An additional object of the present invention is a method of cosmetic treatment to reduce irritant compounds, namely, that a composition comprising at least one adrenergicheskie agonist, applied to the skin, hair and/or mucous membranes.

Another object of the present invention is a method of cosmetic treatment to reduce pain associated with excessive synthesis and/or release of substance P, which consists in the fact that a composition comprising at least one adrenergic agonist, applied to the skin, hair or mucous membranes.

These methods of cosmetic treatment on izobretaia with conventional methods of using these compositions. For example, coating compositions against sunburn or milk to remove make-up, lotions, serums, gels or creams on the skin or to dry hair, applying lotion to the hair on wet hair or shampoos or, alternatively, applying care of teeth on the gums.

The following examples illustrate the invention but without limiting it. Given the proportions in the compositions are the percentage content by weight, unless otherwise indicated.

Example 1: the Pharmacological activity-adrenergic agonist:

Functional in vivo test against the model of neurogenic inflammation

Functional in vivo test carried out in relation to the model of neurogenic inflammation in order to demonstrate the nature of one-adrenergic agonists as an antagonist of substance P in accordance with the method described by Xu X. J. and employees (Neurosciences, 1991, 42, 731-737).

The test is in what is called neurogenic inflammation by antidromic stimulation of nerve saphenous vein of the leg of the animal under anesthesia. This nerve stimulates the areas of skin of the hind legs. Stimulation causes release of substance P from nerve endings, which is partly responsible for neurogenic Inigo Evans, marker for the removal of plasma albumin in the tissue, which occurs during inflammation. This reference model is used in the search for antagonists of substance P in vivo.

The results of this study are summarized in table. 1.

These results represent the average of the results of 8 experiments.

These results demonstrate that, whatever the chemical structure of various compounds of the family-adrenergic agonists, its all these molecules are active type antagonist of the substance P is always in a relatively large extent.

Example 2.

The effect of dose of salbutamol (see tab. 2) in the model antidromic stimulation presented in example 1.

The results demonstrate that the activity of salbutamol in relation to the allocation of substance P depends on the dose. They also exhibit very high activity, about 30 times greater than the activity of the reference molecule, spantide II.

Example 3

Examples of compositions illustrating the invention. These compositions were obtained by simple mixing of the various components.

Composition 1: Lotion for itching

The salbutamol - 0,10%

Antioxidant - a 0.05%

Isopropanol - 40,00%
the Amol - 0,10%

Hydroxypropylcellulose (Klucel H sold by the company Hercules) - 1,00%

Antioxidant - a 0.05%

Isopropanol - 40,00%

Preservative - 0,30%

Water as needed to 100%

Composition 3: Cream facial emulsion oil-in-water)

Isoproterenol - 0,50%

Literallayout - 2,00%

Polysorbate 60 (Tween 60 sold by the company ICI) of 1.00%

Stearic acid - 1,40%

Triethanolamine - 0,70%

Carbomer - 0,40%

The liquid fraction of the seed oil of plants Butyrospermum Parkii - 12,00%

Perhydrosqualene - 12,00%

Antioxidant - a 0.05%

Odorant - 0,50%

Preservative - 0,30%

Water as needed to 100%

Track 4: Shampoo

The salbutamol - 0,05%

Esterified lauryl-sulfate Na (EA 2.2) - 12,00%

Hydroxypropylcellulose (Klucel H sold by the company Hercules) - 1,00%

Odorant - 0,50%

Preservative - 0,30%

Water as needed to 100%

Composition 5: Anesthetic gel

The salbutamol - 0,25%

Hydroxypropylcellulose (Klucel H sold by the company Hercules) - 1,00%

Antioxidant - a 0.05%

Hydrochloride lidocaine - 2,00%

Isopropanol - 40,00%

Preservative - 0,30%

Water as needed to 100%

Track 6: the Cream for the treatment of sunburn (emulsion oil-in-water)

Isoproterenol ICI) - 1,00%

Glycyrrhetic acid is 2.00%

Triethanolamine - 0,70%

Carbomer - 0,40%

The liquid fraction of the seed oil of plants Butyrospermum Parkii - 12,00%

Sunflower oil - 10,00%

Antioxidant - a 0.05%

Odorant - 0,50%

Preservative - 0,30%

Water as needed to 100%

Track 7: Emulsion M/intended for treatment of skin

Fatty phase:

Oil, apricot seed (triglycerides of oleic/linoleic acid) - 14,50%

The liquid fraction of the seed oil of plants Butyrospermum Parkii (triglycerides of palmitic/stearic/oleic/linoleic acids) - 7,00%

Propyl-para-hydroxybenzoate (preservative) - 0,10%

A mixture of fatty alcohols (stearyl alcohol, arachidonoyl alcohol, beganovic alcohol) of 1.00%

Sorbitan the monostearate (Span 60 from ICI) - 2,50%

The mixture cetylstearyl-2-ethylhexanoate and isopropylmyristate (porcelanowe oil) - 2,00%

Aqueous phase:

Preservatives - 0,50%

The disodium salt of ethylenediaminetetraacetic acid 2H2O (complexing agents) - a 0.05%

Neutralizing agent - 0,50%

Gelling agent - 0,70%

Glycerin - 5,00%

Ethoxylated (EO 20), sorbitan the monostearate (Tween 60 from ICI) (surfactant) - 2,50%

5-(n-octanoyl) salicia%

Song 8: Emulsion M/intended for treatment of skin

Fatty phase:

Oil, apricot seed (triglycerides of oleic/linoleic acid) - 14,50%

The liquid fraction of the seed oil of plants Butyrospermum Parkii (triglycerides of palmitic/stearic/oleic/linoleic acids) - 7,00%

Propyl-para-hydroxybenzoate (preservative) - 0,10%

A mixture of fatty alcohols (stearyl alcohol, arachidonoyl alcohol, beganovic alcohol) of 1.00%

Sorbitan the monostearate (Span 60 from ICI) - 2,50%

The mixture cetylstearyl-2-ethylhexanoate and isopropylmyristate (porcelanowe oil) - 2,00%

Aqueous phase:

Preservatives - 0,50%

The disodium salt of ethylenediaminetetraacetic acid 2H2O3(complexing agents) - a 0.05%

Neutralizing agent - 0,50%

Gelling agent - 0,70%

Glycerin - 5,00%

Ethoxylated (EO 20), sorbitan mononuclear (Tween 60 from ICI) (surfactant) - 2,50%

Retinova acid, is 0.025%

The salbutamol - 0,05%

Demineralized or deionized water as needed to 100%I

1. The use of at least one adrenergic agonist as an antagonist of substance P in obtaining compositions intended for the treatment of the ski dermatitis.

2. The use of at least one adrenergic agonist as an antagonist of substance P in obtaining compositions intended for the treatment of sensitive skins.

3. The use according to any one of the preceding paragraphs, characterized in that-adrenergic agonist used as an antagonist of substance P.

4. The use according to any one of the preceding paragraphs, characterized in that the composition is intended for local use.

5. The use according to any one of the preceding paragraphs, characterized in that the composition is intended for the treatment of skin diseases, with the exception of psoriasis and atopic dermatitis.

6. The application of the preceding paragraph, characterized in that the composition is intended for the treatment of diseases with itching, urticaria, contact dermatitis, fibrosis, impaired maturation of collagen and General dermatitis with itching and/or eritem.

7. The use according to any one of the preceding paragraphs, characterized in that the composition is intended to prevent skin irritations and/or sores and/or erythema and/or aesthetic feelings, and/or sensation of heat, and/or itching of the skin and/or mucous membranes-adrenergic agonist used in the range from 10-8up to 10 wt.% calculated on the total weight of the composition.

9. The application of the preceding paragraph, characterized in that-adrenergic agonist used in the range from 10-5up to 4 wt.% calculated on the total weight of the composition.

10. The use according to any one of the preceding paragraphs, characterized in that-adrenergic agonist selected from salbutamol, isoproterenol, CGP12177, nylidrin, salmeterola, fenoterola, terbutalina or pirbuterol.

11. The application of the preceding paragraph, characterized in that-adrenergic agonist is salbutamol.

12. The use of-adrenergic agonist as an antagonist of substance P in obtaining compositions intended for application to the skin, hair and/or mucous membranes, with the aim of reducing pain associated with excessive synthesis and/or release of substance P.

13. The use of-adrenergic agonist as an antagonist of substance P in obtaining compositions containing active ingredients with irritating intended for application to the skin, hair and/or mucous membranes.

14. Cosmetic or pharmaceutical composition having an antagonistic action of the Dean of the active ingredient with the irritant effect characterized in that it further comprises at least one adrenergic agonist.

15. Cosmetic or pharmaceutical composition according to p. 14, characterized in that it is designed for outdoor application.

 

Same patents:

The invention relates to medicine, namely to dermatology
The invention relates to medicine applies balm-ointment for the treatment of deep and extensive burns and infected wounds and ulcers

The invention relates to chemical-pharmaceutical industry, refers to a stable solution palmitate, treatment of skin diseases and reducing the side effects of chemotherapy for cancer patients

- cyano)-,-diphenylethylamine, use,- diphenylacetamide or (-cyano)-,- diphenylacetate, the method of stabilization of the composition and method of cosmetic treatment of the skin and/or hair" target="_blank">

The invention relates to novel cosmetic and/or dermatological compositions comprising cosmetically and/or dermatologically acceptable medium, 4-tert.-butyl-4'-methoxybenzanilide at least one derivative of 1,3,5-triazine, at least,-diphenylacetamide or (-cyano)-,-diphenylethylamine, as well as to a method of stabilization and to a method of cosmetic treatment of the skin and/or hair

The invention relates to the development of safe and effective tools that increase the speed of delivery of physiologically active agents through the skin or mucous membrane of the mouth

The invention relates to medicine and the pharmaceutical industry and relates to a means of stimulating the reparative processes in tissues
The invention relates to medicine, namely to pharmaceutical compositions for removal of benign growths on the skin and mucous membranes (papillomas, warts, nevi, warts, cutaneous cysts, xantom, atheroma, angiomas, keloid scars, as well as cervical erosion), and methods of obtaining such funds
The invention relates to medicine and can be used to prepare therapeutic baths, body wraps, facial masks, etc
The invention relates to medicine and cosmetic industry and relates to curative and preventive cosmetic

The invention relates to the field of dentistry and the receipt of the product for teeth whitening and treatment of skin diseases of the mucous membranes

The invention relates to cosmetic and is a means to care for the skin, in particular lotion, cosmetic alcohol containing propolis extract thick, herbal Supplement "Erakond, ethyl alcohol and water

The invention relates to medicine, namely can be used for treatment and cosmetic skin care
The invention relates to medicine and can be used to prepare therapeutic baths, body wraps, facial masks
The invention relates to medicine, namely to dermatology

Mask for skin care // 2164131
The invention relates to cosmetics

The invention relates to the chemistry of aminoalcohols, in particular, to an improved process for the preparation of tramadol - 2-dimethyl aminomethyl-1-(3-methoxyphenyl)cyclohexanol
Up!